Production (Stage)
InnoCan Pharma Corporation
INNPF
$0.114
-$0.007-5.79%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 61.49% | 115.55% | 192.24% | 271.49% | 388.86% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 61.49% | 115.55% | 192.24% | 271.49% | 388.86% |
| Cost of Revenue | 40.31% | 93.68% | 158.30% | 236.93% | 391.29% |
| Gross Profit | 64.36% | 118.61% | 196.52% | 275.76% | 388.53% |
| SG&A Expenses | 36.28% | 85.09% | 123.05% | 167.99% | 151.27% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 32.72% | 75.75% | 112.09% | 153.06% | 136.27% |
| Operating Income | 112.11% | 67.20% | 71.69% | 33.35% | 34.38% |
| Income Before Tax | 153.96% | 122.79% | 107.23% | 25.72% | 8.23% |
| Income Tax Expenses | 169.87% | 451.87% | 134,300.00% | 92,500.00% | 44,700.00% |
| Earnings from Continuing Operations | 121.53% | 93.83% | 78.14% | -5.58% | -1.96% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -122.65% | -247.02% | -295.29% | -483.25% | -12,166.67% |
| Net Income | 87.51% | 60.98% | 48.19% | -37.12% | -18.63% |
| EBIT | 112.11% | 67.20% | 71.69% | 33.35% | 34.38% |
| EBITDA | 113.17% | 67.84% | 72.31% | 33.71% | 34.68% |
| EPS Basic | 88.83% | 63.39% | 51.52% | -29.13% | -11.93% |
| Normalized Basic EPS | 93.55% | 68.10% | 60.00% | -20.73% | -13.76% |
| EPS Diluted | 87.82% | 62.30% | 50.51% | -27.69% | -10.06% |
| Normalized Diluted EPS | 93.55% | 68.10% | 60.00% | -20.73% | -13.76% |
| Average Basic Shares Outstanding | 8.84% | 8.87% | 8.77% | 7.43% | 4.91% |
| Average Diluted Shares Outstanding | 8.84% | 8.87% | 8.77% | 7.43% | 4.91% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |